Previous studies have indicated that HHLA2 was more frequently expressed than PDCD1 in ccRCC, and HHLA2/PDCD1 co‐expression had an adverse impact on the prognoses of patients with ccRCC, indicating that combination immunotherapy with anti‐HHLA2 and PD‐L1 blockade may function as a new strategy for ccRCC patients. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.